Evidence map›Paper›PMID 33928470›Full record

ArticleActa neurologica Belgica2022

Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study.

Gabriele S Merki-Feld, Peter S Sandor, Rossella E Nappi, Heiko Pohl, Christoph Schankin

Open access · hybridAbstract read
In one paragraph

Article in Acta neurologica Belgica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Gabriele S Merki-FeldDepartment of Reproductive Endocrinology, University Hospital Zürich, Frauenklinikstrasse 10, CH-8091, Zürich, Switzerland. gabriele.merki@usz.ch.ORCID http://orcid.org/0000-0002-8644-773X
Peter S SandorRehaClinic Group, Bad Zurzach, Switzerland.
Rossella E NappiCenter for Reproductive Medicine, Gynecological Endocrinology and Menopause, Obstetrics and Gynecology Unit, IRCCS S. Matteo Foundation, Pavia, Italy.
Heiko PohlDepartment of Neurology, University Hospital Zurich, Zürich, Switzerland.
Christoph SchankinDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
University Hospital of Zurich · CHUniversity of Bern · CHUniversity of Pavia · ITUniversity of Zurich · CHZHAW Zurich University of Applied Sciences · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies have described the features of menstrually related migraines but there is a lack of knowledge regarding the features of migraine in combined hormonal contraceptive users (CHC). Hormone-withdrawal migraines in the pill-free period could differ from those in the natural cycle. Gynaecologic comorbidities, like dysmenorrhea and endometriosis, but also depression or a family history might modify the course of migraine. A better understanding of migraine features linked to special hormonal situations could improve treatment. For this prospective cohort study, we conducted telephone interviews with women using a CHC and reporting withdrawal migraine to collect information on migraine frequency, intensity, triggers, symptoms, pain medication, gynaecologic history and comorbidities (n = 48). A subset of women agreed to also document their migraines in prospective diaries. The mean number of migraine days per cycle was 4.2 (± 2.7). Around 50% of these migraines occurred during the hormone-free interval. Migraine frequency was significantly higher in women who suffered from migraine before CHC start (5.0 ± 3.1) (n = 22) in comparison to those with migraine onset after CHC start (3.5 ± 2.1) (n = 26). Menstrually related attacks were described as more painful (57.5%), especially in women with migraine onset before CHC use (72%) (p < 0.02). Comorbidities were rare, except dysmenorrhea. The majority of migraine attacks in CHC users occur during the hormone-free interval. Similar as in the natural cycle, hormone-withdrawal migraines in CHC users are very intense and the response to acute medication is less good, especially in those women, who developed migraine before CHC use.

Indexed as

Hormonal ContraceptionMigraine DisordersDysmenorrheaFemaleHormonesHumansProspective StudiesHormonesContraceptionFamily historyHormone withdrawalMenstrual migraineMigraine

Identifiers

PMID33928470
PMCPMC8986701
OpenAlexW3158179302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.